{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:14:07Z","timestamp":1792012447583,"version":"4.4.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA264620"],"award-info":[{"award-number":["U01CA264620"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xcrm.2025.102425","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:51:08Z","timestamp":1763502668000},"page":"102425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-0256","authenticated-orcid":false,"given":"Eric F.","family":"Medina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Farmaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason I.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea H.","family":"Bild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-4203","authenticated-orcid":false,"given":"Aritro","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102425_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102425_bib2","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102425_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib4","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib6","first-page":"524","article-title":"Breast Cancer Statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102425_bib7","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","article-title":"Metastasis dormancy in estrogen receptor-positive breast cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-021-00269-x","article-title":"Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge","volume":"7","author":"Bushnell","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102425_bib9","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1074\/jbc.273.23.14484","article-title":"Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism","volume":"273","author":"Hara","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102425_bib11","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity","volume":"10","author":"deGraffenried","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib12","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102425_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Hormone-Positive Breast Cancer","volume":"80","author":"Nunnery","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2025.102425_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102425_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940939","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer","volume":"12","author":"du Rusquec","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102425_bib18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.xcrm.2025.102425_bib19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102425_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"Grabiner","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102425_bib23","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1038\/s41467-018-05639-x","article-title":"Systems biology approach reveals a link between mTORC1 and G2\/M DNA damage checkpoint recovery","volume":"9","author":"Hsieh","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102425_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coph.2009.07.004","article-title":"Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation","volume":"9","author":"Tanti","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102425_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2025.102425_bib26","doi-asserted-by":"crossref","first-page":"56698","DOI":"10.18632\/oncotarget.18082","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway activates autophagy and compensatory Ras\/Raf\/MEK\/ERK signalling in prostate cancer","volume":"8","author":"Butler","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102425_bib27","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102425_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.20628","article-title":"Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways","volume":"49","author":"Chen","year":"2010","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.xcrm.2025.102425_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-010-0928-6","article-title":"Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer","volume":"122","author":"Sabine","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.981962","article-title":"Predicting clinical response to everolimus in ER+ breast cancers using machine-learning","volume":"9","author":"Nath","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xcrm.2025.102425_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib32","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/bioinformatics\/btw216","article-title":"ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information","volume":"32","author":"Lachmann","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102425_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.3593","article-title":"Functional characterization of somatic mutations in cancer using network-based inference of protein activity","volume":"48","author":"Alvarez","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102425_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102425_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2025.102425_bib36","series-title":"Statistical Methods for Research Workers","author":"Fisher","year":"1932"},{"key":"10.1016\/j.xcrm.2025.102425_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrg3472","article-title":"Meta-analysis methods for genome-wide association studies and beyond","volume":"14","author":"Evangelou","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2025.102425_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The Combination of Estimates from Different Experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.xcrm.2025.102425_bib39","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/bioinformatics\/btr511","article-title":"survcomp: an R\/Bioconductor package for performance assessment and comparison of survival models","volume":"27","author":"Schroder","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102425_bib40","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2105-7-S1-S7","article-title":"ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context","volume":"7","author":"Margolin","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102425_bib41","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0394632017734459","article-title":"Immunological effects of everolimus in patients with metastatic renal cell cancer","volume":"30","author":"Huijts","year":"2017","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102425_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110798","article-title":"Everolimus treatment enhances inhibitory immune checkpoint molecules' expression in monocyte-derived dendritic cells","volume":"85","author":"Naseri","year":"2024","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.xcrm.2025.102425_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1006\/geno.1997.4972","article-title":"Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer","volume":"45","author":"Carmeci","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.xcrm.2025.102425_bib45","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.1074\/jbc.M010884200","article-title":"Insulin and insulin-like growth factor I receptors utilize different G protein signaling components","volume":"276","author":"Dalle","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib46","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/onc.2012.97","article-title":"Insulin-like growth factor-I regulates GPER expression and function in cancer cells","volume":"32","author":"De Marco","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102425_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41559-020-01385-w","article-title":"Using ecological coexistence theory to understand antibiotic resistance and microbial competition","volume":"5","author":"Letten","year":"2021","journal-title":"Nat. Ecol. Evol."},{"key":"10.1016\/j.xcrm.2025.102425_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071831","article-title":"The RHO Family GTPases: Mechanisms of Regulation and Signaling","volume":"10","author":"Mosaddeghzadeh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2025.102425_bib49","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1038\/ncomms8866","article-title":"A draft network of ligand-receptor-mediated multicellular signalling in human","volume":"6","author":"Ramilowski","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102425_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/er.2017-00073","article-title":"Insulin Receptor Isoforms in Physiology and Disease: An Updated View","volume":"38","author":"Belfiore","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.xcrm.2025.102425_bib51","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.str.2020.05.002","article-title":"How IGF-II Binds to the Human Type 1 Insulin-like Growth Factor Receptor","volume":"28","author":"Xu","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.xcrm.2025.102425_bib52","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/j.1460-2075.1993.tb05842.x","article-title":"The SH2\/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling","volume":"12","author":"Skolnik","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2025.102425_bib53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0215(20001001)88:1<44::AID-IJC7>3.0.CO;2-8","article-title":"RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells","volume":"88","author":"Martinez-Lacaci","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102425_bib54","doi-asserted-by":"crossref","first-page":"34651","DOI":"10.1074\/jbc.M105894200","article-title":"Galpha i2 enhances in vivo activation of and insulin signaling to GLUT4","volume":"276","author":"Song","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib55","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1541-7786.MCR-22-0090","article-title":"Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma","volume":"20","author":"Elangovan","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102886","article-title":"Mechanisms of resistance to mTOR inhibitors","volume":"147","author":"Formisano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2025.102425_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/msb.2010.31","article-title":"A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers","volume":"6","author":"Lefebvre","year":"2010","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.xcrm.2025.102425_bib58","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3389\/fgene.2019.01180","article-title":"Master Regulators of Signaling Pathways: An Application to the Analysis of Gene Regulation in Breast Cancer","volume":"10","author":"Tapia-Carrillo","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2025.102425_bib59","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1038\/sj.onc.1209432","article-title":"Tumorigenic activity of p21Waf1\/Cip1 in thymic lymphoma","volume":"25","author":"De la Cueva","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102425_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-022-01502-6","article-title":"KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin\/c-Myc signaling pathway","volume":"24","author":"Yin","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib61","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/MCB.01443-12","article-title":"SWI\/SNF chromatin-remodeling factor Smarcd3\/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling","volume":"33","author":"Jordan","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102425_bib62","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1101\/gad.10.17.2117","article-title":"Diversity and specialization of mammalian SWI\/SNF complexes","volume":"10","author":"Wang","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2025.102425_bib63","article-title":"Cardiac-enriched BAF chromatin-remodeling complex subunit Baf60c regulates gene expression programs essential for heart development and function","volume":"7","author":"Sun","year":"2018","journal-title":"Biol. Open"},{"key":"10.1016\/j.xcrm.2025.102425_bib64","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102425_bib65","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.cell.2023.10.006","article-title":"Global identification of SWI\/SNF targets reveals compensation by EP400","volume":"186","author":"Martin","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102425_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102425_bib67","doi-asserted-by":"crossref","first-page":"22020","DOI":"10.1073\/pnas.1909998116","article-title":"Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes","volume":"116","author":"Nath","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102425_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110269","article-title":"A functional module states framework reveals transcriptional states for drug and target prediction","volume":"38","author":"Qin","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102425_bib69","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib70","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1593\/neo.09398","article-title":"Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations","volume":"11","author":"Ciuffreda","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.xcrm.2025.102425_bib71","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib72","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib73","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102425_bib74","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset","volume":"5","author":"Seashore-Ludlow","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102425_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.xcrm.2025.102425_bib76","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102425_bib77","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/or.2015.3767","article-title":"Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer","volume":"33","author":"Imamura","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.xcrm.2025.102425_bib78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2018.00006","article-title":"Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning","volume":"9","author":"Langhans","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102425_bib79","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85898","article-title":"ONC201\/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer","volume":"12","author":"Farmaki","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102425_bib80","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-013-0034-2","article-title":"Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer","volume":"73","author":"Dhillon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2025.102425_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040982","article-title":"Master Regulator Analysis of the SARS-CoV-2\/Human Interactome","volume":"9","author":"Guzzi","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.xcrm.2025.102425_bib82","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12863-022-01047-9","article-title":"Network-based inference of master regulators in epithelial membrane protein 2-treated human RPE cells","volume":"23","author":"Wan","year":"2022","journal-title":"BMC Genom. Data"},{"key":"10.1016\/j.xcrm.2025.102425_bib83","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41467-023-35796-7","article-title":"Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma","volume":"14","author":"Ferguson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102425_bib84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-020-05997-5","article-title":"The SWI\/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer","volume":"185","author":"Tropee","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib85","article-title":"Molecular analysis of TCGA breast cancer histologic types","volume":"1","author":"Thennavan","year":"2021","journal-title":"Cell Genom."},{"key":"10.1016\/j.xcrm.2025.102425_bib86","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-18-0279","article-title":"Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R\/InsR Inhibitors","volume":"24","author":"Nagle","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102425_bib87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.molcel.2017.06.033","article-title":"Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1\/2 Inhibition","volume":"67","author":"Yoon","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102425_bib88","doi-asserted-by":"crossref","first-page":"21468","DOI":"10.18632\/oncotarget.25133","article-title":"Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer","volume":"9","author":"Kimura","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102425_bib89","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102425_bib90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.xcrm.2025.102425_bib91","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming Endocrine Resistance in Breast Cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102425_bib92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1095\/biolreprod.109.076117","article-title":"Estrogen rapidly activates the PI3K\/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus","volume":"81","author":"Kazi","year":"2009","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.xcrm.2025.102425_bib93","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/JME-15-0086","article-title":"Estrogen receptor ESR1 mediates activation of ERK1\/2, CREB, and ELK1 in the corpus of the epididymis","volume":"54","author":"Cavalcanti","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.xcrm.2025.102425_bib94","doi-asserted-by":"crossref","first-page":"16677","DOI":"10.1074\/jbc.M312288200","article-title":"Transcription factors and nuclear receptors interact with the SWI\/SNF complex through the BAF60c subunit","volume":"279","author":"Debril","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib95","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1096\/fasebj.9.5.7896011","article-title":"Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding","volume":"9","author":"Pappas","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.xcrm.2025.102425_bib96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1095\/biolreprod.105.050070","article-title":"Membrane initiated estrogen signaling in breast cancer","volume":"75","author":"Song","year":"2006","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.xcrm.2025.102425_bib97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-007-9618-4","article-title":"Estrogen receptors outside the nucleus in breast cancer","volume":"108","author":"Levin","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib98","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/physrev.00024.2016","article-title":"Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.xcrm.2025.102425_bib99","doi-asserted-by":"crossref","first-page":"18447","DOI":"10.1074\/jbc.M910345199","article-title":"Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway","volume":"275","author":"Kahlert","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102425_bib100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/mend.16.1.0758","article-title":"Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.xcrm.2025.102425_bib101","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2407-12-291","article-title":"Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells","volume":"12","author":"Gaben","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2025.102425_bib102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-016-3829-5","article-title":"ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling","volume":"157","author":"Gelsomino","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122282","article-title":"SMARCD3 Overexpression Promotes Epithelial-Mesenchymal Transition in Gastric Cancer","volume":"16","author":"Park","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102425_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082373","article-title":"Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma","volume":"15","author":"Sun","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102425_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111415","article-title":"MEK inhibitor trametinib combined with PI3K\/mTOR inhibitor BEZ-235 as an effective strategy against NSCLC through impairment of glucose metabolism","volume":"124","author":"Liu","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.xcrm.2025.102425_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/annonc\/mdu482","article-title":"A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors","volume":"26","author":"Tolcher","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102425_bib108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2025.102425_bib109","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102425_bib110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Watson","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102425_bib111","doi-asserted-by":"crossref","first-page":"85120","DOI":"10.18632\/oncotarget.19461","article-title":"A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib","volume":"8","author":"O'Shea","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102425_bib112","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-010-0967-z","article-title":"The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study","volume":"128","author":"Macaskill","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib113","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-008-0027-0","article-title":"A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women","volume":"114","author":"Murray","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102425_bib114","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1158\/2159-8290.CD-22-0342","article-title":"OncoLoop: A Network-Based Precision Cancer Medicine Framework","volume":"13","author":"Vasciaveo","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102425_bib115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/mt.2008.6","article-title":"A multicolor panel of novel lentiviral \u201cgene ontology\u201d (LeGO) vectors for functional gene analysis","volume":"16","author":"Weber","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102425_bib116","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12935-020-01337-1","article-title":"Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model","volume":"20","author":"Grolmusz","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xcrm.2025.102425_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2025.102425_bib118","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/bioinformatics\/btw817","article-title":"Planning bioinformatics workflows using an expert system","volume":"33","author":"Chen","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102425_bib119","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102425_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102425_bib121","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:45:17Z","timestamp":1766177117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":121,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2666379125004987"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102425","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102425"}}